Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Technologies, Inc. Announces the Issuance of Two New Platform Patents

NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced the United...
August 09, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Inc. Appoints Dr. Jonathan Eckard as Chief Scientific Affairs Officer

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
August 07, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Technologies Inc. (Nasdaq: TYME) to Ring The Nasdaq Stock Market Opening Bell

NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
August 02, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Receives Notice of Allowance of Patent for SM-88 in China

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
July 27, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Announces Uplisting to NASDAQ Capital Market Under New Symbol “TYME” on July 31, 2017

NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
July 24, 2017 09:12 ET | Source: Tyme Technologies Inc

Tyme Inc. to Present at Precision: Lung Cancer World R&D Summit

NEW YORK, July 24, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that Dr....
June 12, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Technologies to Present at 2017 Marcum Microcap Conference

NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
June 05, 2017 09:00 ET | Source: Tyme Technologies Inc

Tyme Technologies Presents Positive Interim Clinical Data in Recurrent, Non-Metastatic Prostate Cancer at ASCO 2017

CHICAGO, June 05, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI) today presents positive interim data from an ongoing Phase Ib/II clinical trial (NCT02796898) evaluating the safety,...
May 22, 2017 08:30 ET | Source: Tyme Technologies Inc

Tyme Technologies to Present New Clinical Data for Investigational Drug Candidate SM-88 at 2017 ASCO Annual Meeting

NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
March 29, 2017 09:33 ET | Source: Tyme Technologies Inc

Tyme Technologies Announces Two New Board of Director Appointments -- David Carberry and James Biehl

NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a specialty biotechnology company developing cancer therapeutics targeted at multiple tumor types, today announced...